Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer

Press/Media

Period2 Oct 2018

Media coverage

1

Media coverage

  • TitleStudy of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer
    Media name/outletClinical Trials.gov
    Country/TerritoryUnited States
    Date2/10/18
    PersonsDeirdre Cohen